VEGFA and ovarian cancer: For example, the sole mAb licensed in the UK for the treatment of ovarian cancer is Bevacizumab (Avastin), which targets vascular endothelial growth factor A (VEGF-A), a molecule abundantly secreted by TAMs and fibroblasts to drive neo-angiogenesis and ascites formation [7].